Siamab Therapeutics is a biopharmaceutical company developing therapies targeting cancers that express abnormal carbohydrates/glycans.

 

They have developed a technology platform that enables the discovery of large numbers of highly specific, high-affinity anti-TACA therapeutic antibodies.

 

Siamab has brought together a leading team of scientists and advisors in oncology, glycoimmunology, and antibody engineering to support our anti-TACA antibody discovery and development programs.

​